Controlled drug delivery ocular implants and methods of using same
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
1. A drug delivery ocular implant comprising:
an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;
at least a first drug positioned within said interior lumen;
a cap configured for interaction with the proximal end of said outer shell,
wherein said cap comprises at least one aperture;
a membrane positioned between said cap and said proximal end of said outer shell,
wherein said membrane is permeable or semi-permeable to said at least a first drug,
wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end,
wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least a first drug to occur through said membrane,
wherein said membrane has elastic properties and is configured to self-lock the membrane against the cap to retain the membrane in place;
at least one fluid inflow pathway and one fluid outflow pathway positioned adjacent the distal end of said outer shell,
wherein said at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway; and
a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the ocular implant at a target tissue site.
2. The implant of claim 1 , wherein said membrane has a thickness of between about 50 and about 100 microns.
3. The implant of claim 2 , wherein said at least a first drug elutes from said ocular implant for a period of time ranging from about 12 to about 24 months.
4. The implant of claim 1 , wherein said membrane has a thickness of between about 90 and about 200 microns.
5. The implant of claim 4 , wherein said at least a first drug elutes from said ocular implant for a period of time ranging from about 24 to about 48 months.
6. The implant of claim 1 , further comprising a distally-positioned seal limiting fluid communication between the interior lumen and an ocular space in which the implant is positioned to that occurring through the membrane.
7. The implant of claim 1 , wherein said physiological outflow pathway is Schlemm's Canal.
8. The implant of claim 1 , wherein said at least ene a first drug comprises a prostaglandin, a prostaglandin analog, a prostaglandin inhibitor, and/or combinations thereof.
9. A drug delivery ocular implant comprising:
an outer shell having an open proximal end, a distal end, said outer shell being shaped to define an interior cavity;
at least one drug positioned within said interior cavity;
a retainer configured for interaction with the open proximal end of said outer shell,
wherein said retainer allows for at least one aperture;
a membrane permeable or semi-permeable to said at least one drug positioned distal to the retainer,
wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least one drug to occur through said membrane,
wherein said membrane has elastic properties and is configured to self-lock the membrane against the retainer to retain the membrane in place;
at least one fluid inflow pathway positioned proximal to the distal end of said outer shell,
wherein at least one fluid outflow pathway is configured to deliver ocular fluid from an anterior chamber to a physiological outflow pathway; and
a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the drug delivery ocular implant in an anterior chamber of an eye.
10. The drug delivery ocular implant of claim 9 , wherein said physiological outflow pathway is Schlemm's Canal.
11. The drug delivery ocular implant of claim 9 , wherein said at least one drug comprises a prostaglandin, a prostaglandin analog, a prostaglandin inhibitor, and/or combinations thereof.
12. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is a Rho-kinase inhibitor.
13. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is cyclosporine.
14. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is cyclosporine A.
15. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is moxifloxacin.
16. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is an anti-glaucoma medication.
17. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is a steroid.
18. The drug delivery ocular implant according to claim 9 , wherein the at least one drug is bimatoprost, latanoprost, travoprost or unoprostone.
19. A drug delivery ocular implant comprising:
an outer shell having an open proximal end, a closed distal end, said outer shell being shaped to define an interior cavity;
at least one drug positioned within said interior cavity;
a retainer configured to be positioned over the open proximal end of said outer shell,
wherein said retainer comprises at least one orifice;
a membrane positioned distal to said retainer,
wherein said membrane is permeable or semi-permeable to said at least one drug,
wherein said membrane covers said at least one orifice, thereby controlling elution of said at least one drug through said membrane,
wherein said membrane has elastic properties and is configured to self-lock the membrane against the retainer to retain the membrane in place;
at least one fluid outflow pathway positioned proximal to the distal end of said outer shell,
wherein at least one fluid pathway is configured to deliver ocular fluid from an anterior chamber to a physiological outflow pathway; and
a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the drug delivery ocular implant at a target tissue site in an eye.